The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
Open accessAbstract
OBJECTIVE: To evaluate the efficacy and safety of three dosing and repeat treatment regimens of rituximab (RTX) plus MTX in patients with active RA. METHODS: Patients with active RA despite stable MTX (10-25 mg/week) were randomly assigned to one of the three treatment regimens comprising two courses of RTX given 24 weeks apart: 2 x 500 and 2 x 500 mg; 2 x 500 and 2 x 1000 mg (dose escalation); and 2 x 1000 and 2 x 1000 mg. The primary endpoint was proportion of patients achieving ACR20 at Week 48. RESULTS: At Week 48, ACR20 responses were not statistically significantly different between the dose regimens. Compared with RTX 2 x 500 mg (n = 134) or dose escalation (n = 119), ACR and European League Against Rheumatism (EULAR) outcomes in the RTX 2 x 1000 mg group (n = 93) were consistently higher, with significantly more patients achieving EULAR responses (P = 0.0495). At Week 48, rituximab 2 x 1000 mg was associated with a higher proportion of patients who, following retreatment, maintained or improved their Week 24 responses. Dose escalation from 2 x 500 to 2 x 1000 mg did not appear to be associated with improved outcomes compared with continual 2 x 500 mg. All RTX regimens demonstrated comparable safety. CONCLUSIONS: RTX 2 x 500 and 2 x 1000 mg could not be clearly differentiated, although some efficacy outcomes suggest improved outcomes in the rituximab 2 x 1000 mg group. Retreatment from Week 24 resulted in a sustained suppression of disease activity through to Week 48.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Self-citationPatient-reported outcomes and their role in the assessment of rheumatoid arthritis
Lubeck, D. P. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422001-00004 · Cited by 123
Cited by
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Self-citationvan Vollenhoven, R. F., Emery, P., Bingham, C. O., Keystone, E. C., Fleischmann, R. M., Furst, D. E., Tyson, N., Collinson, N., & Lehane, P. B. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201956 · Cited by 390
Self-citationKim, S.-H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.154 · Cited by 295
Targeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Metadata
- Authors
- Rubbert-Roth, A., Tak, P. P., Zerbini, C., Tremblay, J.-L., Carreno, L., Armstrong, G., Collinson, N., Shaw, T. M., & on behalf of the MIRROR Trial Investigators
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-12
- Volume
- 49
- Issue
- 9
- Pages
- 1683-1693
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2143214745
- Cited by
- 186
- References
- 3
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). https://app.cochat.ai/papers/10.1093/rheumatology/keq116
- The paper
- Rubbert-Roth, A., Tak, P. P., Zerbini, C., Tremblay, J.-L., Carreno, L., Armstrong, G., Collinson, N., Shaw, T. M., & on behalf of the MIRROR Trial Investigators. (2010). Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology. https://doi.org/10.1093/rheumatology/keq116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.